A carregar...

Mitochondrial DNA damage as a potential biomarker of LRRK2 kinase activity in LRRK2 Parkinson’s disease

Leucine-rich repeat kinase 2 (LRRK2) is a promising therapeutic target for the treatment of Parkinson’s disease (PD) and LRRK2 kinase inhibitors are currently being tested in early phase clinical trials. In order to ensure the highest chance of success, a biomarker-guided entry into clinical trials...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Sci Rep
Main Authors: Gonzalez-Hunt, C. P., Thacker, E. A., Toste, C. M., Boularand, S., Deprets, S., Dubois, L., Sanders, L. H.
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2020
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7557909/
https://ncbi.nlm.nih.gov/pubmed/33057100
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-020-74195-6
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!